Skip to content

Patient Centricity and PV Are Big Themes in Japan

TransCelerate has wrapped a whirlwind week in Japan, hitting the road internationally for the first time since the pandemic started.

CEO Dalvir Gill, COO Janice Chang, Program Director Ashley Pachter, and Senior Manager, Communications & Engagement Brian Egan met with TransCelerate Member Community colleagues, external stakeholders, and the PMDA over the past few days.

On Monday, more than 275 Astellas colleagues across Japan and China joined TransCelerate leaders for a TransCelerate Day at the Astellas offices in Tokyo. These days are a chance for Member Company employees to receive in-person updates about our recent solution launches, or for those more unfamiliar with us, get introduced to TransCelerate.

After opening remarks from Dalvir Gill, Janice Chang gave an overview of TransCelerate and highlighted opportunities and impact across our portfolio. Then, one of our Member Company leaders Emily Bachman (Astellas) gave an overview of the TransCelerate impact at Astellas before a session on Patient Experience by Shin Omuru and Intelligent Automation Opportunities by Kouji Kawamura. 

TransCelerate and Astellas colleagues gather for a TransCelerate Day.

Later that day, we met with the Japan Pharmaceutical Manufacturers Association (JPMA) where we gave them a preview of the activities of our Japan Country Network team in 2022 and our recent progress. JPMA also shared the complementary projects that they are conducting.

From there, we met with the R&D Heads Club, which included a lively discussion on our Digital Data Flow and our latest release of the Study Definition Repository Reference Implementation alongside Microsoft, Accenture, and CDISC.

Tuesday brought meetings with the leadership team at Japan CRO Association (JCROA). Those attendees were particularly interested in our Modernizing Clinical Trial Conduct Initiative and Intelligent Automation Opportunities in Pharmacovigilance Initiatives.

Another insightful meeting with the Japan CRO Association (JCROA).

Closing out the day was a meeting with TransCelerate’s Japan Country Network to discuss the importance of our Japan members driving our mission in the region. It is always a pleasure to engage with our Japanese colleagues who have been amazing champions of our work.

On Wednesday, we had another TransCelerate Day, this time at Novartis. Janice and Brian presented the TransCelerate overview to more than 150 colleagues across Japan, China, and Taiwan before highlighting Novartis’ historical achievements and participation. 

We want to extend a thank you to the fantastic presentations by Japan colleagues to highlight the TransCelerate work being prioritized within Novartis and the opportunities for future contributors. 

Related Blog Posts

Digital Data Flow Discovery Day: The “Art of the Possible”

On the eve of this year’s DPharm conference, TransCelerate hosted its first Digital Data Flow Discovery Day in Boston. The goal of the event was to raise awareness, exchange knowledge, and convene stakeholders from around the R&D industry to demonstrate the implementation of its Digital Data Flow (DDF) solutions, the Unified Study Definitions Model (USDM),…

Illuminating Today’s Problem Solvers at DIA Global 2023

TransCelerate, along with hundreds of sponsors, sites, Health Authorities, technology vendors, and other leaders in the biopharma R&D industry, assembled in Boston last week to attend DIA Global 2023. This year’s theme was “Illuminate,” and TransCelerate did its part by spotlighting our insights and solutions during nine sessions at this year’s event. Patients Front &…

TransCelerate Helps Drive Innovation in Clinical Trials at SCOPE

Last week, seven of our members travelled to Orlando, Florida to represent TransCelerate work at the 2023 Summit for Clinical Ops Executives (SCOPE) conference. Over the course of four days, attendees from sites, sponsors, academia, vendors, and other stakeholders convened to share learnings and new releases that positively impact how clinical trials are designed and…